AIBOTICS, INC.

Aibotics, Inc. (OTC: AIBT) is a pre-revenue biotechnology company focused on psilocybin-based mental health therapeutics. The company has no product revenue; its financing has consisted of convertible notes and common stock issuances, with net cash from financing activities of $529,083 for the year ended December 31, 2025. Aibotics holds a supply agreement with Havn Life Sciences (CSE: HAVN) for naturally derived psilocybin as an Active Pharmaceutical Ingredient, intended for use by universities, researchers, and pharmaceutical companies developing psilocybin-based treatments. The company also pursues integration with parent-affiliated Ehave, Inc. (OTC: EHVVF) EEG brain-cap technology to capture neurological data during psilocybin therapy. General and administrative expenses were $1,846,856 for the year ended December 31, 2025, consisting primarily of consulting fees, legal and professional services, and board compensation. The company carried a net loss of $1,848,275 for the year ended December 31, 2024 and reported a going-concern qualification in its consolidated financial statements as of December 31, 2025.